A research-active consultant at CCC has presented encouraging new findings from the PIVOTALboost clinical research trial at ESTRO 2026, one of the world’s leading radiotherapy congresses.
Prof Isabel Syndikus travelled to Sweden's capital Stockholm to give a presentation at the weekend on findings from the prostate cancer study, a major UK phase 3 randomised trial that she led.
The study is evaluating whether treatment intensification strategies can improve outcomes for men with localised prostate cancer at higher risk of recurrence.
The results of the clinical trial – in which CCC was the top recruiter – showed that delivering radiotherapy to the prostate and pelvic lymph nodes over 20 treatments was feasible and did not increase long-term side effects over two years, adding important new evidence for the treatment of men with high-risk localised prostate cancer.
Prof Syndikus, Consultant Clinical Oncologist at CCC and Chief Investigator of the PIVOTALboost trial, said: “These findings are encouraging because they show we can intensify treatment for men with higher-risk prostate cancer using a shorter radiotherapy schedule without seeing an increase in long-term side effects at two years.
"That is an important step in understanding how we can improve treatment safely while we continue to assess the longer-term outcomes from the trial.”
